BioDuro-Sundia vs Certara

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/bioduro-sundia/certara

Category	BioDuro-Sundia	Certara
Listed site	cro	cro
Summary	BioDuro-Sundia is a contract research, development, and manufacturing organization (CRDMO) with 30 years of expertise providing integrated drug discovery, development, and manufacturing services from target identification through IND submission.	Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
Services	Discovery Research Target Identification & Validation High-Throughput Screening Computational & In-Silico Drug Discovery Medicinal Chemistry In Vitro Pharmacology In Vitro ADME / DMPK Safety Pharmacology Genetic Toxicology Preclinical In Vitro Studies In Vivo Efficacy Models In Vivo PK / PD Studies GLP Toxicology Specialized & Large-Animal Models Preclinical In Vivo Studies Bioanalysis Biomarker Assays Flow Cytometry Services Analytical Method Development & Validation ICH Stability Studies Translational Research US FDA Regulatory Strategy China NMPA Regulatory Strategy Regulatory Affairs Immunogenicity Assays (ADA / NAb) Oncology Specialty Services Immunology & Inflammation Services	Biostatistics & Statistical Programming Data Management & eClinical Regulatory Affairs Medical Writing Computational & In-Silico Drug Discovery Translational Research Target Identification & Validation High-Throughput Screening Medicinal Chemistry In Vitro Pharmacology In Vitro ADME / DMPK Safety Pharmacology Genetic Toxicology Discovery Research In Vivo Efficacy Models In Vivo PK / PD Studies GLP Toxicology Preclinical In Vitro Studies Preclinical In Vivo Studies Bioanalysis LC-MS Bioanalysis (Small Molecule) Ligand-Binding Bioanalysis (Large Molecule) Phase I Clinical Trials Biomarker Assays Phase II Clinical Trials Phase III Clinical Trials Clinical Operations Phase IV / Post-Marketing US FDA Regulatory Strategy US FDA Regulatory Strategy EU EMA Regulatory Strategy EU EMA Regulatory Strategy Japan PMDA Regulatory Strategy Japan PMDA Regulatory Strategy China NMPA Regulatory Strategy China NMPA Regulatory Strategy Clinical Trial Services
Modalities	Small Molecule Biologics (Monoclonal Antibodies) Biologics (Other) Antibody-Drug Conjugate (ADC) Peptide	Small Molecule Small Molecule Biologics (Monoclonal Antibodies) Biologics (Monoclonal Antibodies) Biologics (Other) Biologics (Other) Peptide Peptide Oligonucleotide Oligonucleotide mRNA mRNA Antibody-Drug Conjugate (ADC) Antibody-Drug Conjugate (ADC) Gene Therapy Gene Therapy Cell Therapy Cell Therapy Vaccine Vaccine
Indications	Oncology Immunology Neurology Metabolic Respiratory	Oncology Rare Disease Immunology Immunology Neurology Neurology Psychiatry Metabolic Metabolic Cardiovascular Cardiovascular Infectious Disease Infectious Disease Respiratory Respiratory Dermatology Dermatology Ophthalmology Ophthalmology Gastroenterology Gastroenterology Nephrology Nephrology Women's Health Women's Health
Locations	Headquarters, Irvine, California, United States	Global network Global presence, 30 countries Global presence, Multiple, 30 countries, Global Global presence, Multiple, 30+ countries Global presence, Multiple, 30 countries, International Headquarters, Radnor, Pennsylvania, United States Global presence, 30 countries Global presence, 30+ countries
Certifications	Data not yet provided.	Data not yet provided.
Reviews	Review summary appears after site-level review signal gate opens.	Review summary appears after site-level review signal gate opens.